Castle Biosciences expects 2022 revenue to exceed top end of $132-137M guidance

CASTLE BIOSCIENCES INC

2022-FY EPS reported -$2.58 revenue$137,039,000

Total test reports in 2022: 44,338, up 58% YoY from 28,118.
DecisionDx-Melanoma volume 27,797 (+37% YoY); DecisionDx-SCC 5,966 (+70% YoY).
Year-end cash & short-term investments ~$259M ($123M cash + $136M short-term).
Q4 2022 test reports 12,563 (+52% YoY from 8,242); TissueCypher and IDgenetix newly contributed.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.7

CASTLE BIOSCIENCES INC updated its the year ended December 31, 2022 guidance (reaffirmed).

Period: the year ended December 31, 2022
Guidance: reaffirmed
Result: preliminary results

Exact text from the filing

The Company expects to meet or exceed the top end of its previously guided range of $132–137 million for full-year 2022 total revenue.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.7

CASTLE BIOSCIENCES INC reported preliminary financial results for the fourth quarter of 2022.

Period: the fourth quarter of 2022
Result: preliminary results

Exact text from the filing

On January 8, 2023, Castle Biosciences, Inc. (the “Company”) issued a press release announcing certain preliminary performance results for the fourth quarter of 2022 and for the year ended December 31, 2022.

View on SEC.gov

Browse all earnings releases →

CASTLE BIOSCIENCES INC filing history →

Source: SEC EDGAR

accession 0001447362-23-000007

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.